Condition: Treatment of Spontaneous Intracerebral Hemorrhage · Sponsor: First Affiliated Hospital of Fujian Medical University
This is a nationwide, multicenter, open-label, randomized controlled trial of early minimally invasive treatment for deep-seated spontaneous cerebral hemorrhage (dICH). The study consists of 2 steps: the first step is to conduct a dose climbing test to determine the safety and optimal dose of urokinase intra-hematoma irrigation after stereotactic aspiration; the second step is to validate whether stereotactic aspiration plus urokinase irrigation (the optimal dose determined in step one) is superior to conservative treatment in improving long-term outcomes (1 year) in early (within 24h) dICH patients.
This description comes directly from the study's public registry record.
Lin Fuxin, PHD,MD · +86 13552358381 · lfxstuy@126.com
Kang Dezhi, MD · +86 13859099988 · kdz999888@163.com
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04686877